Why Omeros (OMER) Is Up 27.5% After Swinging To Profitability And Completing Share Buyback

Simply Wall St.08-18

Omeros Corporation recently reported second-quarter and half-year 2026 results showing a move from net losses to net income of US$13.23 million and US$69.29 million respectively, while also completing...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660455737?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-08-18 08:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660455737","market":"hk","top_or_hot":-1,"title":"Why Omeros (OMER) Is Up 27.5% After Swinging To Profitability And Completing Share Buyback","media":"Simply Wall St.","content":"<div>\n<p>Omeros Corporation recently reported second-quarter and half-year 2026 results showing a move from net losses to net income of US$13.23 million and US$69.29 million respectively, while also completing...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/why-omeros-omer-is-up-275-after-swinging-to-profitability-an\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Omeros (OMER) Is Up 27.5% After Swinging To Profitability And Completing Share Buyback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Omeros (OMER) Is Up 27.5% After Swinging To Profitability And Completing Share Buyback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-18 08:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/why-omeros-omer-is-up-275-after-swinging-to-profitability-an><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Omeros Corporation recently reported second-quarter and half-year 2026 results showing a move from net losses to net income of US$13.23 million and US$69.29 million respectively, while also completing...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/why-omeros-omer-is-up-275-after-swinging-to-profitability-an\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PMDE","symbol_name":"PGIM S&P 500 Max Buffer ETF - December","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/why-omeros-omer-is-up-275-after-swinging-to-profitability-an","article_id":"2660455737","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/why-omeros-omer-is-up-275-after-swinging-to-profitability-an","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660455737","pubTimestamp":1787013007,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Omeros Corporation recently reported second-quarter and half-year 2026 results showing a move from net losses to net income of US$13.23 million and US$69.29 million respectively, while also completing a share repurchase of 843,187 shares for US$9.87 million under its December 2025 buyback program.\nAlongside this earnings turnaround, Omeros expanded its board to nine members and added veteran financier Joseph Schocken to both the board and audit committee, potentially influencing capital...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PMDE":"PGIM S&P 500 Max Buffer ETF - December","GXDW":"Global X Dorsey Wright Thematic ETF","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","JOYT":"JPMorgan Equity and Options Total Return ETF","OMER":"奥麦罗制药","BK4007":"制药","VGFPF":"Vanguard Funds PLC","VOTE":"TCW Transform 500 ETF","RGLO":"Global Equity Active ETF","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF"},"translate_title":"为什么 Omeros (OMER) 在扭亏为盈并完成股票回购后上涨 27.5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DECU":0.71,"GXDW":0.71,"FEBU":0.71,"RGLO":0.71,"VOTE":0.71,"OMER":1.5,"JOYT":0.71,"PMDE":0.71,"VGFPF":0.71},"content_text":"Omeros Corporation recently reported second-quarter and half-year 2026 results showing a move from net losses to net income of US$13.23 million and US$69.29 million respectively, while also completing a share repurchase of 843,187 shares for US$9.87 million under its December 2025 buyback program. Alongside this earnings turnaround, Omeros expanded its board to nine members and added veteran financier Joseph Schocken to both the board and audit committee, potentially influencing capital allocation and governance as the company advances its pipeline and financing plans, including a US$142.67 million ESOP-related shelf registration. We’ll now examine how this shift to profitability, combined with governance changes, could influence Omeros’s previously outlined investment narrative. We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementOmeros Investment Narrative RecapTo own Omeros today, you need to believe YARTEMLEA can sustain meaningful TA TMA revenues while the broader pipeline matures, and that recent profitability is more than one off. The latest net income swing and modest buyback help the story, but the near term catalyst still centers on commercial execution for YARTEMLEA and any EMA re examination outcome, while a key risk is how dependent both earnings and liquidity remain on a single drug and partnered milestones. Among the recent announcements, the US$142.67 million ESOP related shelf stands out alongside the earnings jump. It reinforces how much of the investment case still ties back to employee driven execution on YARTEMLEA launch and the complement pipeline, even as accounting gains and buybacks influence near term earnings per share. For me, this keeps attention firmly on how durable operating profitability looks once noncash items and capital markets tools fade into the background. Yet behind the move to profitability, the concentration risk around a single new product is something investors should be aware of... Read the full narrative on Omeros (it's free!)Omeros' narrative projects $297.9 million revenue and $23.8 million earnings by 2029. This requires 211.1% yearly revenue growth and a $60.2 million earnings decrease from $84.0 million today.Uncover how Omeros' forecasts yield a $33.00 fair value, a 90% upside to its current price.Exploring Other PerspectivesOMER 1-Year Stock Price Chart Before this news, the most optimistic analysts were assuming revenue could reach about US$1.2 billion and earnings about US$664.6 million, which is far more upbeat than a thesis focused on execution risk around YARTEMLEA uptake; their view shows how far expectations can stretch, and it is a useful contrast as you weigh how the latest profitability and governance changes might shift those forecasts.Explore 3 other fair value estimates on Omeros - why the stock might be worth just $33.00!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Omeros research is our analysis highlighting 4 key rewards and 4 important warning signs that could impact your investment decision.Our free Omeros research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Omeros' overall financial health at a glance.Seeking Other Investments?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660455737","isCrawlerRequest":true}